TREFOIL BINDING PROTEINS IN GASTRIC CARCINOGENESIS

$110,848P20FY2010RRNIH

Rhode Island Hospital, Providence RI

Investigators

Linked publications & trials

Paper 32957908 Paper 30908642 Paper 29856983 Paper 28500033 Paper 27454292 Paper 26905589 Paper 26827872 Paper 26231887 Paper 24658061 Paper 24431073 Paper 24103426 Paper 24098947 Paper 23909495 Paper 23758142 Paper 23528430 Paper 23503644 Paper 23238937 Paper 23066033 Paper 22890274 Paper 22815788 Paper 22807456 Paper 22796065 Paper 22740472 Paper 22662230 Paper 22613460 Paper 22525806 Paper 22520159 Paper 22397685 Paper 22334690 Paper 22012689 Paper 21864488 Paper 21841827 Paper 21761302 Paper 21706493 Paper 21691200 Paper 21689459 Paper 21653738 Paper 21610323 Paper 21544836 Paper 21531004 Paper 21526744 Paper 21389767 Paper 21333769 Paper 21276449 Paper 21186030 Paper 20826784 Paper 20814934 Paper 20812760 Paper 20655306 Paper 20228068 Paper 20140209 Paper 20110408 Paper 20079801 Paper 19887917 Paper 19819359 Paper 19818772 Paper 19816606 Paper 19800103 Paper 19786612 Paper 19768705 Paper 19696631 Paper 19609759 Paper 19415527 Paper 19389930 Paper 19360914 Paper 19294690 Paper 19291737 Paper 18992917 Paper 18927283 Paper 18593995 Paper 18483365 Paper 18477483 Paper 18440304 Paper 18436015 Paper 18413749 Paper 18408592 Paper 18320565 Paper 18279833 Paper 18191800 Paper 18043244 Paper 17947454 Paper 17900656 Paper 17654460 Paper 17620388 Paper 17504014 Paper 17403674 Paper 17379646 Paper 17277770 Paper 17227963 Paper 17174320 Paper 17085646 Paper 17075582 Paper 17021035 Paper 17020779 Paper 16896212 Paper 16766229 Paper 16739230 Paper 16707484 Paper 16641130 Paper 16636048

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Gastric cancer, a major cause of mortality worldwide, is usually preceded by pylori infection. Recognition of H. pylori's role in gastric cancer development affords novel opportunities to study the molecular and cellular events of gastric carcinogenesis and discover novel gastric cancer biomarkers. These insights may lead to the identification of patients at highest gastric cancer risk, and have prognostic and therapeutic applications. In the first COBRE funding cycle, we evaluated the mechanisms and consequences of p27 down-regulation by H. pylori, garnering R01 funding to continue. This new pilot proposal builds upon our recent analysis of the gastric epithelial cell transcriptome of H. pylori infection in vivo. We used laster capture microdissection and gene chips identified, 2 novel related genes (gastrokine [GKN] 1 and 2) that were highly significantly decreased in expression in H. pylori infected tissues were selected for further study. Our focus on GKN1 and 2 is because (i) Gastrokine 2 (GKN2) was the gene whose expression was the most down-regulated by H. pylori, (ii) decreased expression of gastrokines 1 &2 were recently reported in small gastric cancer series by others, and confirmed by us to be lost in a large proportion of cases in gastric cancer, and (iii) biological plausibility-GKN2 interacts with trefoil factor family proteins involved in gastric mucosal repair, H. pylori adherence and carcinogenesis. We hypothesize that (1) GKN1 and GKN2 are regulated by H. pylori and act as gastric cancer tumor suppressors: and (2) expression of GKN1 and GKN2 may serve as gastric cancer biomarkers. These hypotheses will be tested over 2 years by (1) examining the cellular effects of alterations in GKN1 and GKN2 in gastric cells in vitro and in vivo and (2) by evaluating the utility of GKN1 and GKN2 as biomarkers of gastric cancer susceptibility in a prospectively clinical study of H. pylori-infected patients and in a mouse model of H. pylori-induced gastric cancer.

View original record on NIH RePORTER →